Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
about
Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinomaTargeting reactive oxygen species in development and progression of pancreatic cancer.Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model.Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression.Investigation of Polyamine Metabolism and Homeostasis in Pancreatic Cancers.
P2860
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@ast
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@en
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@nl
type
label
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@ast
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@en
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@nl
prefLabel
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@ast
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@en
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@nl
P2093
P2860
P1476
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
@en
P2093
Alessandro Paniccia
Barish H Edil
Justin Merkow
P2860
P304
P356
10.3978/J.ISSN.1000-9604.2015.05.01
P407
P577
2015-08-01T00:00:00Z